Actively Recruiting
Type 1 Diabetes Recurrence in Pancreas Transplants
Led by University of Miami · Updated on 2025-01-16
400
Participants Needed
1
Research Sites
1095 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The hypothesis is that humoral and cellular islet-specific responses are an early risk factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney (SPK) recipients independent of alloimmunity. This study will test the hypothesis and will assess their individual and combined predictive value.
CONDITIONS
Official Title
Type 1 Diabetes Recurrence in Pancreas Transplants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (24 months)
- Age 18-75 years
- Recipient of simultaneous pancreas and kidney transplant
- Primary or secondary renal allograft: living or deceased
You will not qualify if you...
- Patient has previously received or is receiving an organ transplant other than a pancreas-kidney
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Miami Miller School of Medicine Transplant Clinic
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
G
George Burke, M.D.
CONTACT
L
Lissett Moni
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here